Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Tiotropium bromide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Trokide contains the active substance tiotropium. It helps people who have chronic obstructive pulmonary disease (COPD) to breathe more easily. COPD is a chronic lung disease that causes shortness of breath and coughing. The term COPD is associated with the conditions chronic bronchitis and emphysema. As COPD is a chronic disease you should take Trokide every day and not only when you have breathing problems or other symptoms of COPD. Trokide is a long-acting bronchodilator that helps to open your airways and makes it easier to get air in and out of the lungs. Regular use of Trokide can also help you when you have ongoing shortness of breath related to your disease and will help you to minimise the effects of the disease on your everyday life. It also helps you to be active longer. Daily use of Trokide will also help to prevent sudden, short-term worsening of your COPD symptoms which may last for several days.
e Trokide Do not use Trokide:
Warnings and precautions
Talk to your doctor or pharmacist before using Trokide.
Children and adolescents
Trokide is not recommended for children and adolescents under 18 years.
Other medicines and Trokide
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines available without prescription. Please tell your doctor or pharmacist if you are using/have used similar medicines for your lung disease, such as ipratropium or oxitropium. No specific side effects have been reported when Trokide has been used together with other products used to treat COPD such as reliever inhalers, e.g. salbutamol, methylxanthines, e.g. theophylline and/or oral and inhaled steroids, e.g. prednisolone.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not use this medicine unless specifically recommended by your doctor.
Driving and using machines
The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery.
Trokide contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. Lactose contains small amounts of milk proteins which may cause allergic reactions.
Trokide Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is to inhale the contents of 1 capsule (18 micrograms of tiotropium) once a day. You must breathe in 2 times from the same capsule (see section "Instructions for handling and use" at the end of this leaflet). Do not use more than the recommended dose. You should try to use the capsule at the same time every day. This is important because Trokide is effective over 24 hours. Use Trokide capsules only with the Vertical-Haler.
Use in children and adolescents
Trokide is not recommended for children and adolescents under 18 years.
Method of administration
The capsules are only for inhalation and not for oral intake. Do not swallow the capsules. The Vertical-Haler, which you should put the Trokide capsule into, makes holes in the capsule and allows you to breathe in the powder. Make sure that you have a Vertical-Haler and that you can use it properly. The instructions for use of the Vertical-Haler are provided at the end of this leaflet. Detailed instructions on how to use Trokide with the Vertical-Haler are provided at the end of this leaflet, "Instructions for handling and use". If you have any problems using the Vertical-Haler, ask your doctor or pharmacist to show you how it works. If you feel that your breathing is worsening, you should tell your doctor as soon as possible.
If you use more Trokide than you should
If you inhale from more than 1 capsule of Trokide in a day, you should talk to your doctor immediately. You may be at a higher risk of experiencing a side effect such as dry mouth, constipation, difficulties passing urine, increased heart beat, or blurred vision.
If you forget to use Trokide
If you forget to take a dose, take one as soon as you remember but do not use two doses at the same time or on the same day. Then take your next dose as usual. Do not use a double dose to make up for a forgotten dose.
If you stop using Trokide
Before you stop using Trokide, you should talk to your doctor or your pharmacist. If you stop using this medicine the signs and symptoms of COPD may worsen. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects described below have been experienced by people using this medicine. Serious side effects include allergic reactions which cause swelling of the face or throat (angioedema) or other hypersensitivity reactions (such as sudden reduction of your blood pressure or dizziness) may occur individually or as part of severe allergic reaction (anaphylactic reaction) after administration of Trokide. In addition, some patients may experience an unexpected tightness of the chest, coughing, wheezing or breathlessness immediately after inhalation (bronchospasm). If any of these occur, please consult your doctor immediately. Other side effects Common (may affect up to 1 in 10 people)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
2. Opening To open the Vertical-Haler, hold it with the mouthpiece upwards and press the "^" marked area (as shown on the enlarged picture) with your fingertip. Open the inhaler by pulling the mouthpiece up and away from the base as shown (Fig 2).
3. Inserting the capsule Insert the capsule shell inside the nest of the capsule chamber (Fig.3). Please note: The capsule should only be removed from the blister immediately before using the inhaler.
Make sure that the capsule shell is correctly inserted (Fig. 4).
Trokide Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the outer carton and blister strip after "expiry date" or "EXP". The expiry refers to the last day of that month. Do not store above 30°C. Discard the inhaler 90 days after first use. The capsule should be used directly after opening the blister. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Trokide contains
4. Closing the compartment Close the mouthpiece firmly until you hear a 'click' (Fig. 5).
5. Piercing the capsule Hold the Vertical-Haler with the mouthpiece upwards. Press the button completely in only once and release (Fig.6).
The active substance is tiotropium. Each capsule contains 22.5 microgram tiotropium bromide monohydrate equivalent to 18 microgram tiotropium.
This will make holes in the capsule and allows the medicine to be released when you breathe in.
The delivered dose (the dose that leaves the mouthpiece of the inhaler) is 10 microgram tiotropium.
Attention: In case you need to repeat Step 5, open the capsule compartment (Fig.2) to make sure the capsule shell is correctly inserted in the nest cavity (Fig.4).
The other ingredient is lactose monohydrate (which may contain small amounts of milk proteins). The capsule shell contains gelatin, water, polyethylene glycole 4000, titanium dioxide (E171), yellow iron oxide (E172) and FD&C Blue 1/ Brilliant Blue FCF.
What Trokide looks like and contents of the pack
Trokide is an opaque, green capsule with a size of 16 mm x 5.8 mm containing the inhalation powder. Aluminium / Aluminium blister containing 5 to 10 capsules. Trokide is available in the following packs:
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder STADA, Linthwaite, Huddersfield, HD7 5QH, United Kingdom
6. Prepare to use Hold the Vertical-Haler away from your mouth and breathe out completely. (Fig.7) Do not breathe into the Vertical-Haler at any time. 7. Inhalation Keep your head in an upright position and close your lips tightly around the mouthpiece. Breathe in slowly and deeply (Fig.8). You will hear a vibrating sound of the capsule rotating inside the capsule chamber for dispersion of the drug. Breathe in until your lungs are full; then hold your breath as long as comfortable and at the same time take the Vertical-Haler out of your mouth. Resume normal breathing
Manufacturer
Repeat steps 6 and 7 one more time. You must breathe in 2 times from the same capsule.
Other formats
Attention: When holding the inhaler during inhalation, make sure not to block the air inlet openings located on the sides of the mouthpiece. This can impede the air to flow inside the inhaler, reducing the capsule movement, and drug dispersion. Do not push the mouthpiece down during inhalation. This can block the capsule movement.
Pharmadox Healthcare Ltd., KW20A Kordin Industrial Park, Paola, PLA3000, Malta To request a copy of this leaflet in braille, large print or audio please call 01484 848164.
This leaflet was last revised in May 2024 Instructions for handling and use
Remember to carefully follow your doctor's instructions for using Trokide. The Vertical- Haler is especially designed for Trokide. You must not use it to take any other medication. You can use your Vertical-Haler for up to 90 days to take your medication. The Vertical-Haler – explanation of different parts 1 Cap 2 Mouthpiece 3 Base 4 Push button 5 Capsule chamber/nest
1. Removing the cap Hold the Vertical-Haler and remove the cap completely by pulling it upwards and away from the base to expose the mouthpiece as shown (Fig. 1).
Cleaning your Vertical-Haler After use, open the mouthpiece. Hold the inhaler facing downwards to remove the capsule from the centre chamber. Close the mouthpiece and place the cap on. This will keep the dry powder inhaler clean and dry. Clean the mouthpiece and the capsule chamber with a clean, dry cloth. Alternatively, a soft, clean brush can be used to remove residual powder inside the centre chamber/nest. If needed, the outside of the mouthpiece should be cleaned with a damp cloth.
Please note: Trokide capsules contain only a small amount of powder so that the capsule is only partially filled.
93076122209 GB
Trokide 18 mcg Inhalation powder, hard capsules comes as capsule containing 18mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Trokide 18 mcg Inhalation powder, hard capsules is tiotropium bromide.
Medicines with the same active substance, strength and form include: Acopair 18 microgram, inhalation powder, hard capsules, Spiriva 18 microgram inhalation powder, hard capsule, Tiogiva 18 microgram, inhalation powder, hard capsule. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Trokide 18 mcg Inhalation powder, hard capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Trokide is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
Posology
The recommended dosage of tiotropium is inhalation of the contents of one capsule once daily with the Vertical-Haler at the same time of day. Two inhalation manoeuvres are to be performed for each capsule.
The recommended dose should not be exceeded.
Tiotropium should only be inhaled with the Vertical-Haler device.
Special populations
Elderly
Elderly patients can use tiotropium at the recommended dose.
Renal impairment
Renally impaired patients can use tiotropium at the recommended dose. For patients with moderate to severe impairment (creatinine clearance ≤ 50 ml/min) see section 4.4 and section 5.2.
Hepatic impairment
Hepatically impaired patients can use tiotropium at the recommended dose (see section 5.2).
Paediatric population
COPD
There is no relevant use in the paediatric population (below 18 years) in the indication stated under section 4.1.
Cystic fibrosis
The safety and efficacy of Trokide in children and adolescents has not been established. No data are available.
Method of administration
For inhalation use only.
The capsules must not be swallowed.
The capsule should only be removed from the blister immediately before using the inhaler.
To ensure proper administration of the medicinal product the patient should be trained how to use the inhaler by the physician or by other healthcare professionals.
Instructions for handling and use
The patient must be advised to carefully follow the doctor's instructions for using Trokide. The Vertical-Haler is especially designed for Trokide. It must not be used to take any other medication. The Vertical-Haler can be used for up to 90 days to take the medication. It is a single patient device intended for multiple uses.
Vertical-Haler - explanation of different parts
1 Cap2 Mouthpiece3 Base4 Push button5 Capsule chamber / nest
1. Removing the cap
Hold the Vertical-Haler and remove the cap completely by pulling it upwards and away from the base to expose the mouthpiece as shown (Fig. 1).
2. Opening
To open the Vertical-Haler, hold it with the mouthpiece upwards and press the “˄” marked area (as shown on enlarged picture) with your fingertip. Open the inhaler by pulling the mouthpiece up and away from the base as shown (Fig. 2).
3. Inserting the capsule
Insert the capsule shell inside the nest of the capsule chamber (Fig. 3).
Please note: The capsule should only be removed from the blister immediately before using the inhaler.
Make sure that the capsule shell is correctly inserted (Fig. 4).
4. Closing the compartment
Close the mouthpiece firmly until you hear a “click” (Fig. 5).
5. Piercing the capsule
Hold the Vertical-Haler with the mouthpiece upwards. Press the button completely in only once and release (Fig. 6).
This will make holes in the capsule and allows the medicine to be released when you breathe in.
Attention: In case you need to repeat Step 5, open the capsule compartment (Fig. 2) to make sure the capsule shell is correctly inserted in the nest cavity (Fig. 4).
6. Prepare to use
Hold the Vertical-Haler away from your mouth and breathe out completely (Fig. 7)
Do not breathe into the Vertical-Haler at any time.
7. Inhalation
Keep your head in an upright position and close your lips tightly around the mouthpiece. Breathe in slowly and deeply (Fig. 8). You will hear a vibrating sound of the capsule rotating inside the capsule chamber for dispersion of the drug. Breathe in until your lungs are full; then hold your breath as long as comfortable and at the same time take the Vertical-Haler out of your mouth. Resume normal breathing.
Repeat steps 6 and 7 one more time. You must breathe in 2 times from the same capsule.
Attention:
When holding the inhaler during inhalation, make sure not to block the air inlet openings located on the sides of the mouthpiece. This can impede the air to flow inside the inhaler, reducing the capsule movement, and drug dispersion. Do not push the mouthpiece down during inhalation. This can block the capsule movement.
Cleaning your Vertical-Haler
After use, open the mouthpiece. Hold the inhaler facing downwards to remove the capsule from the capsule chamber. Close the mouthpiece and place the cap on. This will keep the dry powder inhaler clean and dry.
Clean the mouthpiece and the capsule chamber with a clean, dry cloth once a week. Alternatively, a soft, clean brush can be used to remove residual powder inside the centre chamber/nest.
If needed, the outside of the mouthpiece should be cleaned with a damp cloth.
Trokide capsules contain only a small amount of powder so that the capsule is only partially filled.
Hypersensitivity to the active substance, milk proteins or to the excipients listed in section 6.1 or to atropine or its derivatives, e.g., ipratropium or oxitropium.
Tiotropium, as a once daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.e., rescue therapy.
Immediate hypersensitivity reactions may occur after administration of tiotropium inhalation powder.
Consistent with its anticholinergic activity, tiotropium should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. (see section 4.8).
Inhaled medicines may cause inhalation-induced bronchospasm.
Tiotropium should be used with caution in patients with recent myocardial infarction < 6 months; any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in medicinal product therapy in the past year; hospitalisation of heart failure (NYHA Class III or IV) within the past year. These patients were excluded from the clinical trials and these conditions may be affected by the anticholinergic mechanism of action.
As plasma concentration increases with decreased renal function in patients with moderate to severe renal impairment (creatinine clearance ≤ 50 ml/min) tiotropium should be used only if the expected benefit outweighs the potential risk. There is no long-term experience in patients with severe renal impairment (see section 5.2).
Patients should be cautioned to avoid getting the inhalation powder into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema. Should any combination of these eye symptoms develop, patients should stop using tiotropium and consult a specialist immediately.
Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries.
Tiotropium should not be used more frequently than once daily (see section 4.9).
Trokide contains lactose
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. The excipient lactose monohydrate may contain small amounts of milk proteins which may cause allergic reactions.
Although no formal drug interaction studies have been performed, tiotropium inhalation powder has been used concomitantly with other medicinal products without clinical evidence of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, commonly used in the treatment of COPD.
Use of LABA or ICS was not found to alter the exposure to tiotropium.
The co-administration of tiotropium with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Pregnancy
There is a very limited amount of data from the use of tiotropium in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Trokide during pregnancy.
Breast-feeding
It is unknown whether tiotropium is excreted in human breast milk. Despite studies in rodents which have demonstrated that excretion of tiotropium in breast milk occurs only in small amounts, use of tiotropium is not recommended during breast-feeding. Tiotropium is a long-acting compound. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with tiotropium should be made taking into account the benefit of breast-feeding to the child and the benefit of tiotropium therapy to the woman.
Fertility
Clinical data on fertility are not available for tiotropium. A non-clinical study performed with tiotropium showed no indication of any adverse effect on fertility (see section 5.3).
No studies on the effects on the ability to drive and use machines have been performed. The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery.
Summary of the safety profile
Many of the listed undesirable effects can be assigned to the anticholinergic properties of Trokide.
Tabulated list of adverse reactions
The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse drug reactions (i.e. events attributed to tiotropium) observed in the tiotropium group (9647 patients) from 28 pooled placebo-controlled clinical trials with treatment periods ranging from four weeks to four years.
Adverse reactions are listed by System Organ Class and frequency. Frequencies are defined according to the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000), not known (cannot be estimated from the available data).
System Organ Class / MedDRA Preferred Term
Frequency
Metabolism and nutrition disorders
Dehydration
Not known
Nervous system disorders
Dizziness
Uncommon
Headache
Uncommon
Taste disorders
Uncommon
Insomnia
Rare
Eye disorders
Vision blurred
Uncommon
Glaucoma
Rare
Intraocular pressure increased
Rare
Cardiac disorders
Atrial fibrillation
Uncommon
Supraventricular tachycardia
Rare
Tachycardia
Rare
Palpitations
Rare
Respiratory, thoracic and mediastinal disorders
Pharyngitis
Uncommon
Dysphonia
Uncommon
Cough
Uncommon
Bronchospasm
Rare
Epistaxis
Rare
Laryngitis
Rare
Sinusitis
Rare
Gastrointestinal disorders
Dry Mouth
Common
Gastrooesophageal reflux disease
Uncommon
Constipation
Uncommon
Oropharyngeal candidiasis
Uncommon
Intestinal obstruction, including ileus paralytic
Rare
Gingivitis
Rare
Glossitis
Rare
Dysphagia
Rare
Stomatitis
Rare
Nausea
Rare
Dental caries
Not known
Skin and subcutaneous tissue disorders, immune system disorders
Rash
Uncommon
Urticaria
Rare
Pruritus
Rare
Hypersensitivity (including immediate reactions)
Rare
Angioedema
Rare
Anaphylactic reaction
Not known
Skin infection, skin ulcer
Not known
Dry skin
Not known
Musculoskeletal and connective tissue disorders
Joint swelling
Not known
Renal and urinary disorders
Dysuria
Uncommon
Urinary retention
Uncommon
Urinary tract infection
Rare
Description of selected adverse reactions
In controlled clinical studies, the commonly observed undesirable effects were anticholinergic undesirable effects such as dry mouth which occurred in approximately 4 % of patients.
In 28 clinical trials, dry mouth led to discontinuation in 18 of 9647 tiotropium treated patients (0.2 %).
Serious undesirable effects consistent with anticholinergic effects include glaucoma, constipation and intestinal obstruction including ileus paralytic as well as urinary retention.
Other special population
An increase in anticholinergic effects may occur with increasing age.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
High doses of tiotropium may lead to anticholinergic signs and symptoms.
However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 340 microgram tiotropium in healthy volunteers. Additionally, no relevant adverse effects, beyond dry mouth, were observed following 7 day dosing of up to 170 microgram tiotropium in healthy volunteers. In a multiple dose study in COPD patients with a maximum daily dose of 43 microgram tiotropium over four weeks no significant undesirable effects have been observed.
Acute intoxication by inadvertent oral ingestion of tiotropium capsules is unlikely due to low oral bioavailability.
Ask anything about Trokide 18 mcg Inhalation powder, hard capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.